HLB、肝がん一次治療薬（リボセラニブ・カムレリズマブ併用療法）の再承認書類をFDAに提出

MTIMES Global Editorial Statement

This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].